European Respiratory Journal

Papers
(The H4-Index of European Respiratory Journal is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Soteria: deliverance from harm?1254
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan964
The right ventricle tamed810
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis233
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?215
Chymase-1: a “MAST”-er switch in COPD?187
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?171
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease170
Missing airways, ventilation defects and conductive airway physiology in asthma167
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow162
A breath of the future: a novel human model for COPD and beyond158
The lung that rules the heart147
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?144
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis138
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD135
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation126
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target122
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?118
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study114
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?108
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet106
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis106
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)104
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al103
Combining rituximab with mycophenolate for the treatment of interstitial lung disease101
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections100
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis98
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial97
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection97
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey96
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea95
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms88
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe87
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study86
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume84
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD84
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis80
The environmental impact of inhaled therapy: making informed treatment choices79
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor78
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis78
Treatment algorithm for pulmonary arterial hypertension75
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?74
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis72
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?72
No exposure left behind: time to pay attention to children's chemical environment in lung development72
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study71
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment69
WHO online guide on the use of digital technologies for tuberculosis programmes68
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling68
The association between immunosuppressants and outcomes of COVID-1967
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis66
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study66
The limits of normal of pulmonary arterial wedge pressure63
Reply: Tuberculosis screening in migrants to the EU/EEA and UK62
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?62
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough61
Pleural mesothelioma: surgery questioned again?60
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?59
0.22777605056763